Investing.com

TransCode Therapeutics aandeel stijgt na veelbelovende glioblastoomstudie

Investing.com -- Het aandeel van TransCode Therapeutics (NASDAQ:RNAZ) steeg dinsdag met 18% nadat het bedrijf preklinische gegevens publiceerde waaruit blijkt dat hun belangrijkste kandidaat TTX-MC138 ...
Investing.com

TransCode’s glioblastomatherapie toont veelbelovende resultaten in preklinisch onderzoek

Glioblastomapatiënten hebben momenteel een mediane overleving van minder dan twee jaar na diagnose, ondanks standaardbehandelingen. Het bedrijf gaf aan dat de onderzoeken voor het mogelijk maken van ...
Seeking Alpha

TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique ...

TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences Concurrent equity investment of $25 Million from CK Life Sciences into TransCode TransCode expands its ...
Nasdaq

TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial

BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's ...
Seeking Alpha

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA ...
Nasdaq

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market

TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA ...